KRAS and cancer: In the history of medicine, scientists havestrived to overcome diseases more effectivelythrough developing new therapeutic methods.Since the discovery of RNAi in 1998, significantefforts and resources have been invested inexploiting its therapeutic applications (25, 26).The original therapeutic indications for siRNAhave been performed in vivo using viral strains(e.g. HIV, hepatitis B and C, respiratory syncytialvirus, poliovirus and herpes simplex virus)and cancer models (a wide variety of mutatedoncogenes such as K-Ras, mutated p53, Her2/neu, and bcr-abl) (27, 28).